News und Analysen

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 22, 2020. This dividend is payable on February 12, 2021 to

Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, Nov. 5, 2020, following the release of its third

Humana Inc. (NYSE: HUM) today re-confirms its commitment to provide innovative models of care for families through a catalytic investment of $5 million in an outcomes-based fund, supported by

October 22, 2020

ACTIVITY IN THE THIRD QUARTER OF 2020

(Unaudited data)

Cumulative activity as of the end of september 2020

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 5, 2020, to discuss its financial and

ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

University Medical Center New Orleans, a part of LCMC Health, and Humana Inc. (NYSE: HUM), a leading health and well-being company, have signed an in-network agreement, expanding access to care for

Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, has entered into an agreement with DAV (Disabled American Veterans), an organization whose mission is

Pfizer Inc. (NYSE:PFE) today announced the full analysis from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that

Veeva Systems (NYSE: VEEV) today announced the featured keynote speakers at 2020 Veeva Medical Device & Diagnostics Summit Online. Chief medical officers from Boston Scientific, Illumina, Johnson &amp

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005725/en/

Vifor Pharma and Cara Therapeutics, Inc

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report third fiscal quarter 2020 financial